Analysis of serum lipids, cardiovascular risk, and indication
for statin use during nilotinib and imatinib therapy in de novo
CML patients ? results from real-life prospective study

J 2020

Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study

HORŇÁK, Tomáš, Lukáš SEMERÁD, Daniela ŽÁČKOVÁ, Barbora WEINBERGEROVÁ, Zuzana ŠUSTKOVÁ et. al.

Basic information

Original name

Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study

Authors

HORŇÁK, Tomáš (703 Slovakia, belonging to the institution), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Daniela ŽÁČKOVÁ (203 Czech Republic, belonging to the institution), Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Zuzana ŠUSTKOVÁ (203 Czech Republic, belonging to the institution), Jiřina PROCHÁZKOVÁ (203 Czech Republic), Petra BELOHLAVKOVA (203 Czech Republic), Lukas STEJSKAL (203 Czech Republic), Peter ROHON (203 Czech Republic), Edgar FABER (203 Czech Republic), Pavel ZAK (203 Czech Republic), Jiří MAYER (203 Czech Republic, belonging to the institution) and Zdeněk RÁČIL (203 Czech Republic, guarantor, belonging to the institution)

Edition

LEUKEMIA & LYMPHOMA, LONDON, TAYLOR & FRANCIS, 2020, 1042-8194

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 3.280

RIV identification code

RIV/00216224:14110/20:00115331

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1080/10428194.2019.1672054

UT WoS

000489439400001

Keywords in English

serum lipids; cardiovascular risk; nilotinib and imatinib therapy

Abstract

V originále

Tyrosine kinase inhibitors (TKI) have dramatically improved the prognosis of CML patients with life expectancy close to individuals without CML [1], and therefore the longterm safety of TKIs has become especially important due to the potential for lifelong treatment. Nilotinib (NILO) tends to have a negative effect on lipid [2] and glucose [3] metabolism, while imatinib (IMA) seems to improve [4] these abnormalities. Although the data appear convincing, the real impact of these changes on cardiovascular (CV) risk and the development of CV complications during TKI therapy have not yet been confirmed.

Links

LM2018128, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR

NV17-30397A, research and development project

Name: Mutační analýza primitivních buněčných populací u chronické myeloidní leukémie: za hranicí BCR-ABL1

Citovat

HORŇÁK, Tomáš, Lukáš SEMERÁD, Daniela ŽÁČKOVÁ, Barbora WEINBERGEROVÁ, Zuzana ŠUSTKOVÁ, Jiřina PROCHÁZKOVÁ, Petra BELOHLAVKOVA, Lukas STEJSKAL, Peter ROHON, Edgar FABER, Pavel ZAK, Jiří MAYER and Zdeněk RÁČIL. Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study. LEUKEMIA & LYMPHOMA. LONDON: TAYLOR & FRANCIS, 2020, vol. 61, No 2, p. 494-496. ISSN 1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2019.1672054.

@article{1623156,
   author = {Horňák, Tomáš and Semerád, Lukáš and Žáčková, Daniela and Weinbergerová, Barbora and Šustková, Zuzana and Procházková, Jiřina and Belohlavkova, Petra and Stejskal, Lukas and Rohon, Peter and Faber, Edgar and Zak, Pavel and Mayer, Jiří and Ráčil, Zdeněk},
   article_location = {LONDON},
   article_number = {2},
   doi = {http://dx.doi.org/10.1080/10428194.2019.1672054},
   keywords = {serum lipids; cardiovascular risk; nilotinib and imatinib therapy},
   language = {eng},
   issn = {1042-8194},
   journal = {LEUKEMIA & LYMPHOMA},
   title = {Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study},
   url = {https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1672054},
   volume = {61},
   year = {2020}
}

TY  - JOUR
ID  - 1623156
AU  - Horňák, Tomáš - Semerád, Lukáš - Žáčková, Daniela - Weinbergerová, Barbora - Šustková, Zuzana - Procházková, Jiřina - Belohlavkova, Petra - Stejskal, Lukas - Rohon, Peter - Faber, Edgar - Zak, Pavel - Mayer, Jiří - Ráčil, Zdeněk
PY  - 2020
TI  - Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study
JF  - LEUKEMIA & LYMPHOMA
VL  - 61
IS  - 2
SP  - 494-496
EP  - 494-496
PB  - TAYLOR & FRANCIS
SN  - 10428194
KW  - serum lipids
KW  - cardiovascular risk
KW  - nilotinib and imatinib therapy
UR  - https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1672054
L2  - https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1672054
N2  - Tyrosine kinase inhibitors (TKI) have dramatically improved the prognosis of CML patients with life expectancy close to individuals without CML [1], and therefore the longterm safety of TKIs has become especially important due to the potential for lifelong treatment. Nilotinib (NILO) tends to have a negative effect on lipid [2] and glucose [3] metabolism, while imatinib (IMA) seems to improve [4] these abnormalities. Although the data appear convincing, the real impact of these changes on cardiovascular (CV) risk and the development of CV complications during TKI therapy have not yet been confirmed.
ER  -

HORŇÁK, Tomáš, Lukáš SEMERÁD, Daniela ŽÁČKOVÁ, Barbora WEINBERGEROVÁ, Zuzana ŠUSTKOVÁ, Jiřina PROCHÁZKOVÁ, Petra BELOHLAVKOVA, Lukas STEJSKAL, Peter ROHON, Edgar FABER, Pavel ZAK, Jiří MAYER and Zdeněk RÁČIL. Analysis of serum lipids, cardiovascular risk, and indication for statin use during nilotinib and imatinib therapy in de novo CML patients ? results from real-life prospective study. \textit{LEUKEMIA \&{} LYMPHOMA}. LONDON: TAYLOR \&{} FRANCIS, 2020, vol.~61, No~2, p.~494-496. ISSN~1042-8194. Available from: https://dx.doi.org/10.1080/10428194.2019.1672054.

Detailed Information on Publication Record